Taysha Gene Therapies, Inc. (TSHA) saw its stock surge 6.52% during pre-market trading on Thursday. The significant move followed the release of the company's full-year 2025 financial results and a positive corporate update.

The clinical-stage biotech reported a revenue of $9.8 million for 2025, substantially beating the FactSet consensus estimate of $5.9 million. Furthermore, its net loss per share narrowed to $0.34, which was better than the estimated loss of $0.37 and an improvement from the $0.36 loss per share in the prior year. The company also ended the year with a strong cash position of $319.8 million.

Investor sentiment was further bolstered by updates on the company's lead program, TSHA-102 for Rett syndrome. Taysha reported dosing multiple patients in its pivotal REVEAL trial, receiving FDA clearance to initiate the ASPIRE trial, and reaching written alignment with the FDA on key manufacturing and regulatory strategies to support a planned Biologics License Application (BLA) submission. The company stated it is on track to complete dosing in both key trials in the second quarter of 2026.